spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  AVONEX 

 HSMN NewsFeed - 7 Dec 2017
John Walsh, M.D. Joins EMD Serono as Vice President of Neurology & Immunology, US Medical Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Dec 2016
Biogen and AbbVie Receive Health Canada Approval of Once-Monthly ZINBRYTA(TM) (Daclizumab Beta) for Multiple Sclerosis
Biopharmaceuticals Nerurology Regulatory
 HSMN NewsFeed - 28 Sep 2015
Zafgen Announces Transition of Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Apr 2015
Amicus Therapeutics Appoints David Allsop as Senior Vice President, International
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Mar 2015
Chiasma Announces Mark Leuchtenberger as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Apr 2014
Cubist Appoints Robert J. Perez to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jan 2014
Biogen Idec and UCB Enter Agreements to Commercialize Multiple Sclerosis and Hemophilia Therapies in Asia
Biopharmaceuticals Licensing
 HSMN NewsFeed - 6 Feb 2013
Biogen Idec to Acquire Full Rights and Control of TYSABRI(R) from Elan for Upfront Cash and Contingent Payments
Biopharmaceuticals Neurology Acquisitions
 HSMN NewsFeed - 28 Jan 2013
Genzyme’s LEMTRADA(TM) (alemtuzumab) Application for MS Accepted for Review by the FDA
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 20 Aug 2012
Dyax Corp. Creates COO Position and Expands Executive Roles
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Mar 2012
Seattle Genetics Appoints Dr. Nancy Simonian to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Mar 2012
Alkermes Appoints Mark Stejbach as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Feb 2012
FDA Approves AVONEX(R) PEN(TM) and Dose Titration Regimen
Biopharmaceuticals Drug Delivery Neurology FDA
 HSMN NewsFeed - 29 Sep 2011
Biogen Idec Promotes Tony Kingsley to Run Global Commercial Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Sep 2011
Elan Announces Board of Director Changes
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 7 Jun 2011
Biogen Idec Receives Approval in the European Union for AVONEX(R) PEN(TM)
Biopharmaceuticals Drug Delivery Neurology Regulatory
 HSMN NewsFeed - 11 Apr 2011
Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 13 Jan 2011
Anders Lundström to Be the New CEO of Orexo
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jan 2011
Biogen Idec Appoints Doug Williams to Head R&D, Steven Holtzman to Head Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Sep 2010
Biogen Idec Makes Statement About U.S. FDA Approval of Gilenya
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 22 Sep 2010
Novartis gains FDA approval for Gilenya, a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 7 Jan 2010
Lycera Appoints Senior Life Sciences Executive William J. Sibold as President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 May 2009
Avila Therapeutics Appoints Katrine S. Bosley as Company's First CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Sep 2008
Laquinimod Demonstrated Significant and Sustained Impact on Multiple Sclerosis Disease Activity
Biopharmaceuticals Neurology
 HSMN NewsFeed - 18 Sep 2008
New Long-Term Data Show That Patients Taking AVONEX(R) for up to 15 Years Experience Reduced Disability Progression and Improved Quality of Life
Biopharmaceuticals Neurology
 HSMN NewsFeed - 27 Aug 2008
Enrollment Complete in 15-Year Long-Term Follow-Up Study Evaluating Impact of AVONEX(R) in Patients with Relapsing Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 23 Jul 2008
Tengion Appoints Mark Stejbach Vice President of Marketing & Commercial Planning
Regenerative Medicine Personnel
 HSMN NewsFeed - 16 Jul 2008
Teva Enrolls Patients for a Second Large Global Phase III Trial of Oral Laquinimod
Biopharmaceuticals Neurology
 HSMN NewsFeed - 10 Jun 2008
Merck Serono's Rebif(R) Celebrates 10th Anniversary
BIopharmaceuticals Neurology
 HSMN NewsFeed - 29 May 2008
Biogen Idec Names Hans Peter Hasler Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 May 2008
Biogen Idec Celebrates 30 Years of Transforming Discovery into Care
Biopharmaceuticals
 HSMN NewsFeed - 15 Apr 2008
Study Shows that High-Dose, High-Frequency Interferon Produces no Additional Benefit on Efficacy Compared to AVONEX(R) (interferon beta-1a) in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 20 Aug 2007
TYSABRI(R) Demonstrates Significant Health-Related Quality-of-Life Improvements for Multiple Sclerosis Patients in Study Published in Annals of Neurology
Biopharmaceuticals Neurology
 HSMN NewsFeed - 31 Jul 2007
Accentia Biopharmaceuticals Files Pre-Investigational New Drug (IND) Application with FDA for Pivotal Phase 3 Clinical Trial of Revimmune for Refractory Multiple Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 13 Apr 2007
New One-Year Pharmacoeconomic Study Shows AVONEX(R) is Cost-Effective Relative to Other Interferon Therapies for Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 11 Apr 2007
First Pharmacoeconomic Analysis with Long-Term Data Showed COPAXONE(R) Was More Cost-Effective Than Interferon Beta Therapies for Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 20 Oct 2006
AVONEX(R), The #1 Prescribed Multiple Sclerosis Therapy Worldwide, Improves Patient Convenience
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 6 Oct 2006
New Pharmacoeconomic Data on TYSABRI(R) Demonstrate Significant Reduction in Steroid Use and Hospitalizations in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 3 Oct 2006
Long-Term Data Demonstrated Significantly Better Patient Adherence to COPAXONE(R) versus Interferons in Multiple Sclerosis Treatment
Biopharmaceuticals Neurology
 HSMN NewsFeed - 29 Sep 2006
AVONEX(R), the #1 Prescribed Multiple Sclerosis (MS) Therapy Worldwide: New MRI Data Presented
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Sep 2006
New Data Confirmed Antibodies to COPAXONE(R) do not Impact Its Established and Sustained Long-Term Efficacy in Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Sep 2006
New Study: AVONEX(R), The Most Prescribed Multiple Sclerosis Treatment Worldwide, Demonstrates Superior Adherence
Biopharmaceuticals Neurology
 HSMN NewsFeed - 18 Sep 2006
Targanta Appoints Mark Leuchtenberger, Former President and CEO of Therion Biologics Corporation, as President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Aug 2006
First Patient Enrolled in Study to Evaluate Impact of Regular Neutralizing Antibody (NAb) Testing on Multiple Sclerosis Treatment Patterns
Biopharmaceuticals Neurology
 HSMN NewsFeed - 24 Jul 2006
Biogen Idec and Elan Announce Availability of TYSABRI(R) for the Treatment of Relapsing Forms of Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 21 Jun 2006
Mark Matthews Joins Javelin Pharmaceuticals as VP of Commercial Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Jun 2006
AVONEX(R), The Most Prescribed Multiple Sclerosis Therapy Worldwide, May Now Be Given with Smaller Needle
Biopharmaceuticals Drug Delivery Neurology
 HSMN NewsFeed - 20 Jun 2006
COPAXONE(R) Reduced Relapses By 75 Percent in Both Treatment-Naive Multiple Sclerosis Patients and Those Failing Betaseron(R)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 5 Jun 2006
FDA Approves the Reintroduction of TYSABRI(R) for the Treatment of Relapsing Forms of Multiple Sclerosis
Biopharmaceuticals FDA Neurology
 HSMN NewsFeed - 31 May 2006
COPAXONE(R) Reduced Relapses and Stabilized Disability as Measured by Expanded Disability Status Scale, When Avonex(R) Failed
Biopharmaceuticals Neurology
 HSMN NewsFeed - 19 May 2006
AVONEX(R), the Most Prescribed Multiple Sclerosis Therapy Worldwide, Celebrates 10th Anniversary
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Apr 2006
CHMP Issues Positive Opinion for TYSABRI(R) as a Treatment for Relapsing-Remitting Multiple Sclerosis
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 13 Apr 2006
ArQule Announces Management and Board Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Apr 2006
New Data on TYSABRI(R) Demonstrate Significant Effects on Health-Related Quality of Life Measures in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 3 Apr 2006
Newly Published Data Show Early Use of AVONEX(R) Delayed the Risk of Multiple Sclerosis for up to 5 Years
Biopharmaceuticals Neurology
 HSMN NewsFeed - 29 Mar 2006
Mona Haynes Joins Acusphere in Newly Created Position of Vice President, Marketing and Sales
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Mar 2006
TYSABRI(R) Two-Year Phase III Multiple Sclerosis Clinical Trial Results and Safety Evaluation Published in New England Journal of Medicine
Biopharmaceuticals Neurology
 HSMN NewsFeed - 21 Feb 2006
IDM and GENESIS Pharma Sign an Exclusive Marketing Agreement for Junovan(TM) in South East Europe
Biopharmaceuticals Licensing
 HSMN NewsFeed - 23 Jan 2006
Biogen Idec and Elan Announce Notification of FDA Advisory Committee Meeting to Review TYSABRI(R) for the Treatment of Multiple Sclerosis
Biopharmaceuticals FDA Neurology
Return to NewsFeed  

 Additional items found! 46

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 46 additional stories matching:
AVONEX
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.